Watson launches generic of ViroPharma's antibiotic
(Reuters) - Generic drugmaker Watson Pharmaceuticals Inc said U.S. health regulators approved its copycat version of ViroPharma Inc's antibiotic Vancocin.
Separately, ViroPharma said the U.S. Food and Drug Administration declined its citizen petition, which was filed to prevent Watson from launching the generic version.
Shares of ViroPharma were trading down 18 percent at $23.40 in premarket.
Watson said it has started shipping the drug, which recorded sales of $332 million for the 12 months ended February 29, 2012.
ViroPharma shares closed at $28.61 on Monday on the Nasdaq.
(Reporting by Anand Basu in Bangalore; Editing by Sriraj Kalluvila)
- Tweet this
- Share this
- Digg this
- U.S. SEC to pay $30 million-plus in largest whistleblower award
- Housing data hits Wall Street; S&P has worst day since August 5 |
- US STOCKS-Housing data hits Wall St; S&P has worst day since Aug 5
- Housing data hits Wall St; S&P has worst day since Aug 5
- CANADA STOCKS-TSX hits six-week low on China fears, commodity prices
Sierra Leone recorded 130 new cases of the Ebola virus during a three-day lockdown and it is waiting for test results on a further 39 suspected cases, Stephen Gaojia, head of the Ebola Emergency Operations Centre, said on Monday. Full Article
Allowing blood donations from gay men could help save over a million lives: U.S. study. Full Article